Endosense, a Geneva-based medical technology company, has named Nicolas Marsault as its new CFO. Marsault has previously worked in a variety of managerial positions at Merck Serono. He replaces Endosense’s previous chief financial officer, Andrea Buscaglia.
Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has named Nicolas Marsault as its new chief financial officer. Marsault joins the company as it continues to expand the commercial presence of its TactiCath® contact-force sensing ablation catheter in Europe and prepares for the device’s anticipated launch in the United States. His appointment follows the closing of a USD 40.3 million/CHF 37.4 million series C financing round, announced by Endosense on November 27.
“We welcome Nicolas to our team at a pivotal time of growth for the company,” said Jan Keltjens, Endosense president, chief executive officer and chairman of Endosense. “With his strong background in both finance and science, we expect him to play a critical role in the expansion of our business worldwide.”
Marsault brings to Endosense more than 10 years of executive experience in healthcare and industrial finance, with earlier career tenure in engineering. Prior to Endosense, he held various managerial positions within Merck Serono’s commercial controlling, forecasting and internal audit departments, where he developed an expertise in business development in the pharmaceutical industry. During his time at Merck Serono, he, among other achievements, successfully implemented SOX in twelve months; maintained a profitable growth over four years; and negotiated in licensing deals with big pharmaceutical partners. Earlier in his career, Marsault held the position of manager of internal auditing at Saint Gobain, the world leader in the habitat and construction markets, and was also a research engineer at Péchiney (currently ALCAN), a major aluminum conglomerate.
“Endosense is a visionary company with a platform therapeutic technology that has the potential to deliver significant benefit to patients around the world,” said Marsault. “It is a pleasure to join the Endosense team at such an important and exciting time in the company’s history.”
Marsault has replaced Endosense’s previous chief financial officer, Andrea Buscaglia.
Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first contact-force sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Endosense is backed by NDN Capital, Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.
Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.